Article
Oncogenic KRAS is dependent upon an EFR3A-PI4KA signaling axis for potent tumorigenic activity.
Nature communications - 9 Sept 2021
Adhikari Hema, Kattan Walaa E, Kumar Shivesh, Zhou Pei, Hancock John F, Counter Christopher M
Abstract excerpt
The HRAS, NRAS, and KRAS genes are collectively mutated in a fifth of all human cancers. These mutations render RAS GTP-bound and active, constitutively binding effector proteins to promote signaling conducive to tumorigenic growth. To further elucidate how RAS oncoproteins signal, we mined RAS interactomes for potential vulnerabilities. Here we identify EFR3A, an adapter protein for the phosphatidylinositol...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.